| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f255f4e7672286414bee614d7c777e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26514fdcb7ecda81190de8371dbba9e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bc16ff8b0a00f42578dba3da282f865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79e62b64348d61658ebf10330bb0b74b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate |
2010-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7db7e8502680dfcea6490f5d9b90f7e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b578ab365ac64f0626b9dbb635b00a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a19f8cfe2fe8bf0a5277f15b8af8ac5 |
| publicationDate |
2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8653106-B2 |
| titleOfInvention |
Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder |
| abstract |
A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9216176-B2 |
| priorityDate |
2010-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |